Bacillus Calmette-Guérin-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biological Products for Treatment : Draft Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
August 8, 2024
August 9, 2024
3fae8291-7235-49ce-9d2d-1d17d90d4656
Related Documents
Real-World Evidence: Considerations Regarding Non-Interventional Studies for Drug and Biological Products
Guidance DocumentMarch 21, 2024Center for Drug Evaluation and Research
Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment: Draft Guidance for Industry
Guidance DocumentAugust 17, 2020Office of the Commissioner
Biomarker Qualification: Evidentiary Framework: Draft Guidance for Industry and FDA Staff
Guidance DocumentDecember 12, 2018Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox